<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2679241-A1" country="EP" doc-number="2679241" kind="A1" date="20140101" family-id="46721680" file-reference-id="318320" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146550445" ucid="EP-2679241-A1"><document-id><country>EP</country><doc-number>2679241</doc-number><kind>A1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-13173828-A" is-representative="YES"><document-id mxw-id="PAPP154824368" load-source="docdb" format="epo"><country>EP</country><doc-number>13173828</doc-number><kind>A</kind><date>20130626</date><lang>EN</lang></document-id><document-id mxw-id="PAPP188910913" load-source="docdb" format="original"><country>EP</country><doc-number>13173828.8</doc-number><date>20130626</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140448958" ucid="GB-201211634-A" load-source="docdb"><document-id format="epo"><country>GB</country><doc-number>201211634</doc-number><kind>A</kind><date>20120628</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1988105575" load-source="docdb">C07K  16/44        20060101ALI20131011BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988119829" load-source="docdb">A61K  39/385       20060101AFI20131011BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988129750" load-source="docdb">C07D 295/096       20060101ALI20131011BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988137035" load-source="docdb">G01N  33/531       20060101ALI20131011BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1889107197" load-source="docdb" scheme="CPC">C07K2317/90        20130101 LA20161014BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1889107198" load-source="docdb" scheme="CPC">C07K2317/76        20130101 LA20161014BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1889107199" load-source="docdb" scheme="CPC">C07K2317/33        20130101 LA20161014BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1889107200" load-source="docdb" scheme="CPC">C07D 295/096       20130101 LI20161014BHEP        </classification-cpc><classification-cpc mxw-id="PCL1991318330" load-source="docdb" scheme="CPC">C07K  16/44        20130101 FI20140110BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132183819" lang="DE" load-source="patent-office">Assay für Benzylpiperazine und Metaboliten</invention-title><invention-title mxw-id="PT132183820" lang="EN" load-source="patent-office">Assay for benzylpiperazines and metabolites</invention-title><invention-title mxw-id="PT132183821" lang="FR" load-source="patent-office">Dosage pour benzylpiperazines et métabolites</invention-title><citations><patent-citations><patcit mxw-id="PCIT242656603" load-source="docdb" ucid="EP-0902394-A1"><document-id format="epo"><country>EP</country><doc-number>0902394</doc-number><kind>A1</kind><date>19990317</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656604" load-source="docdb" ucid="EP-1227311-A2"><document-id format="epo"><country>EP</country><doc-number>1227311</doc-number><kind>A2</kind><date>20020731</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656605" load-source="docdb" ucid="EP-1354623-A1"><document-id format="epo"><country>EP</country><doc-number>1354623</doc-number><kind>A1</kind><date>20031022</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656606" load-source="docdb" ucid="EP-1434995-A2"><document-id format="epo"><country>EP</country><doc-number>1434995</doc-number><kind>A2</kind><date>20040707</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656608" load-source="docdb" ucid="EP-2261259-A1"><document-id format="epo"><country>EP</country><doc-number>2261259</doc-number><kind>A1</kind><date>20101215</date></document-id><sources><source name="SEA" category="A" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377618297" load-source="docdb" ucid="EP-98307706-A" dnum-type="application"><document-id format="epo"><country>EP</country><doc-number>98307706</doc-number><kind>A</kind><date>19980923</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377621147" load-source="docdb" ucid="EP-98307732-A" dnum-type="application"><document-id format="epo"><country>EP</country><doc-number>98307732</doc-number><kind>A</kind><date>19980923</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656607" load-source="docdb" ucid="US-7153896-B2"><document-id format="epo"><country>US</country><doc-number>7153896</doc-number><kind>B2</kind><date>20061226</date></document-id><sources><source name="SEA" category="X" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656609" load-source="docdb" ucid="WO-2011022089-A1"><document-id format="epo"><country>WO</country><doc-number>2011022089</doc-number><kind>A1</kind><date>20110224</date></document-id><sources><source name="SEA" category="I" created-by-npl="N"/></sources></patcit></patent-citations><non-patent-citations><nplcit><text>ANTIA, U. ET AL., FORENSIC SCI INT, vol. 186, no. 1-3, 2009, pages 63 - 67</text><sources><source mxw-id="PNPL56930599" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>ANTIA, U. ET AL., JFORENSIC SCI, vol. 55, no. 5, 2010, pages 1311 - 1318</text><sources><source mxw-id="PNPL56930600" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>DE BOER DOUWE ET AL: "Piperazine-like compounds: A new group of designer drugs-of-abuse on the European market", FORENSIC SCIENCE INTERNATIONAL, ELSEVIER SCIENTIFIC PUBLISHERS IRELAND LTD, IE, vol. 121, no. 1-2, 1 September 2001 (2001-09-01), pages 47 - 56, XP002538332, ISSN: 0379-0738, DOI: 10.1016/S0379-0738(01)00452-2</text><sources><source mxw-id="PNPL56930601" load-source="docdb" name="SEA" category="I"/></sources></nplcit><nplcit><text>FITZGERALD, S. P. ET AL., CLIN. CHEM., vol. 51, no. 7, 2005, pages 1165 - 1176</text><sources><source mxw-id="PNPL56930602" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>FITZGERALD, S. P., CLIN. CHEM, vol. 51, no. 7, 2005, pages 1165 - 1176</text><sources><source mxw-id="PNPL56930603" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>FITZGERALD, S.P. ET AL., CLIN. CHEM., vol. 51, 2005, pages 1165 - 1176</text><sources><source mxw-id="PNPL56930604" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>GREG T. HERMANSON: "Bioconjugation Techniques", ACADEMIC PRESS, pages: 419 - 455</text><sources><source mxw-id="PNPL56930605" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KEIKO NAKANISHI ET AL: "Cross-reactivities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View(TM), and the Emit assays for use in drug enforcement", FORENSIC SCIENCE INTERNATIONAL, vol. 217, no. 1-3, 1 April 2012 (2012-04-01), pages 174 - 181, XP055083102, ISSN: 0379-0738, DOI: 10.1016/j.forsciint.2011.11.003</text><sources><source mxw-id="PNPL69871731" load-source="docdb" name="SEA" category="I"/></sources></nplcit><nplcit><text>LOGAN, B.K. ET AL., JANAL TOXICOL, vol. 34, 2010, pages 587 - 589</text><sources><source mxw-id="PNPL56930607" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>MOHAMMED ASLAM; ALASTAIR DENT, BIOCONJUGATION, 1998, pages 364 - 482</text><sources><source mxw-id="PNPL56930608" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>NEOGEN: "Neogen ELISA Drug detection", 1 January 2012 (2012-01-01), XP002714505, Retrieved from the Internet &lt;URL:http://www.neogen/toxicology/pdf/Forensic_Reference_Brochure.pdf&gt; [retrieved on 20120101]</text><sources><source mxw-id="PNPL56930609" load-source="docdb" name="SEA" category="ID"/></sources></nplcit><nplcit><text>PETERS, F.T. ET AL., THER DRUG MONIT, vol. 32, no. 5, 2010, pages 532 - 539</text><sources><source mxw-id="PNPL56930610" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>STAACK, R.F.; MAURER, H.H., JANAL TOXICOL, vol. 27, no. 8, 2003, pages 560 - 568</text><sources><source mxw-id="PNPL56930611" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>TSUTSUMI, H. ET AL., JANAL TOXICOL, vol. 30, no. 1, 2006, pages 38 - 43</text><sources><source mxw-id="PNPL56930612" load-source="docdb" name="APP"/></sources></nplcit></non-patent-citations></citations></technical-data><parties><applicants><applicant mxw-id="PPAR918155350" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>RANDOX LAB LTD</last-name><address><country>GB</country></address></addressbook></applicant><applicant mxw-id="PPAR918139479" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>RANDOX LABORATORIES LTD.</last-name></addressbook></applicant><applicant mxw-id="PPAR918987956" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Randox Laboratories Ltd.</last-name><iid>100205694</iid><address><street>Ardmore, 55 Diamond Road</street><city>Crumlin, County Antrim BT29 4QY</city><country>GB</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918144521" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>BENCHIKH ELOUARD</last-name><address><country>GB</country></address></addressbook></inventor><inventor mxw-id="PPAR918171347" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>BENCHIKH, ELOUARD</last-name></addressbook></inventor><inventor mxw-id="PPAR918994221" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>BENCHIKH, ELOUARD</last-name><address><street>Randox Laboratories Ltd 55 Diamond Road</street><city>Crumlin, Antrim BT29 4QY</city><country>GB</country></address></addressbook></inventor><inventor mxw-id="PPAR918151021" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>FITZGERALD PETER</last-name><address><country>GB</country></address></addressbook></inventor><inventor mxw-id="PPAR918134229" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>FITZGERALD, PETER</last-name></addressbook></inventor><inventor mxw-id="PPAR918992124" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>FITZGERALD, PETER</last-name><address><street>Randox Laboratories Ltd 55 Diamond Road</street><city>Crumlin, Antrim BT29 4QY</city><country>GB</country></address></addressbook></inventor><inventor mxw-id="PPAR918136842" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>LOWRY PHILIP</last-name><address><country>GB</country></address></addressbook></inventor><inventor mxw-id="PPAR918161630" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>Lowry, Philip</last-name></addressbook></inventor><inventor mxw-id="PPAR918990614" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>Lowry, Philip</last-name><address><street>Randox Laboratories 55 Diamond Road</street><city>Crumlin, Antrim BT66 7RP</city><country>GB</country></address></addressbook></inventor><inventor mxw-id="PPAR918164247" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>MCCONNELL IVAN</last-name><address><country>GB</country></address></addressbook></inventor><inventor mxw-id="PPAR918135683" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>McConnell, Ivan</last-name></addressbook></inventor><inventor mxw-id="PPAR918993915" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>McConnell, Ivan</last-name><address><street>Randox Laboratories Ltd 55 Diamond Road</street><city>Crumlin, Antrim BT29 4QY</city><country>GB</country></address></addressbook></inventor></inventors></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS548829629" load-source="docdb">AL</country><country mxw-id="DS548857817" load-source="docdb">AT</country><country mxw-id="DS548829631" load-source="docdb">BE</country><country mxw-id="DS548916069" load-source="docdb">BG</country><country mxw-id="DS548811459" load-source="docdb">CH</country><country mxw-id="DS548909066" load-source="docdb">CY</country><country mxw-id="DS548909067" load-source="docdb">CZ</country><country mxw-id="DS548906896" load-source="docdb">DE</country><country mxw-id="DS548829632" load-source="docdb">DK</country><country mxw-id="DS548829633" load-source="docdb">EE</country><country mxw-id="DS548894029" load-source="docdb">ES</country><country mxw-id="DS548916278" load-source="docdb">FI</country><country mxw-id="DS548916279" load-source="docdb">FR</country><country mxw-id="DS548906897" load-source="docdb">GB</country><country mxw-id="DS548829634" load-source="docdb">GR</country><country mxw-id="DS548906946" load-source="docdb">HR</country><country mxw-id="DS548909068" load-source="docdb">HU</country><country mxw-id="DS548811460" load-source="docdb">IE</country><country mxw-id="DS548829635" load-source="docdb">IS</country><country mxw-id="DS548916280" load-source="docdb">IT</country><country mxw-id="DS548829636" load-source="docdb">LI</country><country mxw-id="DS548906947" load-source="docdb">LT</country><country mxw-id="DS548857818" load-source="docdb">LU</country><country mxw-id="DS548906948" load-source="docdb">LV</country><country mxw-id="DS548906949" load-source="docdb">MC</country><country mxw-id="DS548857819" load-source="docdb">MK</country><country mxw-id="DS548857820" load-source="docdb">MT</country><country mxw-id="DS548857821" load-source="docdb">NL</country><country mxw-id="DS548811461" load-source="docdb">NO</country><country mxw-id="DS548857822" load-source="docdb">PL</country><country mxw-id="DS548894030" load-source="docdb">PT</country><country mxw-id="DS548857823" load-source="docdb">RO</country><country mxw-id="DS548894031" load-source="docdb">RS</country><country mxw-id="DS548857824" load-source="docdb">SE</country><country mxw-id="DS548906951" load-source="docdb">SI</country><country mxw-id="DS548811462" load-source="docdb">SK</country><country mxw-id="DS548811463" load-source="docdb">SM</country><country mxw-id="DS548829637" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>ME</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data></bibliographic-data><abstract mxw-id="PA128671112" lang="EN" load-source="patent-office"><p id="pa01" num="0001">The invention relates to the detection and quantification of 1-benzylpiperazine and its metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications.</p></abstract><abstract mxw-id="PA128500485" lang="EN" source="EPO" load-source="docdb"><p>The invention relates to the detection and quantification of 1-benzylpiperazine and its metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications.</p></abstract><description mxw-id="PDES63956542" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b>Background</b></heading><p id="p0001" num="0001">In recent years piperazine derivatives have emerged as a new class of designer drugs, gaining popularity especially among young people in the dance music scene where they are commonly known as 'party pills'. They are often marketed as 'natural' or 'herbal' products but are in fact entirely synthetic chemicals. Coupled with their ease of availability and varying legal status across the globe this can create the misconception that these drugs are safe and without the risks commonly associated with traditional street drugs. Piperazine derivatives are usually found in illicit dosage forms as either tablets or capsules, but loose powders and more rarely solutions also occur. The tablets often carry logos similar to those seen on ecstasy tablets and they are often misleadingly sold as ecstasy or as apparent 'safer' and 'legal' alternatives. Their name derives from the piperazine heterocycle which is a common feature and they can be divided into two sub-classes; the benzylpiperazines, such as 1-benzylpiperazine (BZP) itself, and the phenylpiperazines which include 1-(3-chlorophenyl)piperazine (mCPP), 1-(4-methoxyphenyl)piperazine (MeOPP) and 1-(3-Trifluoromethylphenyl)piperazine (TFMPP).</p><p id="p0002" num="0002">Synonyms for BZP include 1-(phenylmethyl)piperazine, 1-Benzyl-1,4-diazacyclohexane and N-benzylpiperazine. Street names include A2, Bliss, Charge, Frenzy, Herbal ecstasy, Legal E and Legal X.</p><p id="p0003" num="0003">1-Benzylpiperazine is metabolized in mammals by ring hydroxylation of the aromatic ring , N-dealkylation, O-methylation and conjugation. Tsutsumi <i>et al</i> (2006) suggested that <i>p</i>-OH-BZP is the most relevant target analyte for use in forensic toxicological and clinical analysis of BZP intake since it retains the structural identity of the parent. Their study, conducted on Wistar rats, found that urinary levels of the parent BZP peaked at around 4hrs post-dosing, while the levels of the OH-BZP metabolites <i>p</i>-OH-BZP and <i>m</i>-OH-BZP (4-OH-BZP and 3-OH-BZP) reached maximum levels around 8hrs post-dosing. After the peak they found that levels of BZP and its OH metabolites in urine dropped rapidly, with BZP becoming undetectable at 48hrs post dosing while the <i>p</i>-OH-BZP and <i>m-</i>OH-BZP were detectable up to 48hrs post-dosing. Of the doses given in the study 6.7% was excreted unchanged as the parent BZP, 25% as p-OH-BZP (the most abundant primary metabolite) and 2% as m-OH-BZP. BZP can be detected in the plasma within 30 min of an oral dose of BZP hydrochloride, with peak plasma concentrations occurring between 60 and 90 min post ingestion (Anita <i>et al</i> 2009). BZP has an elimination half life of 5-6 hrs and elimination is complete by around 44 hrs.<!-- EPO <DP n="2"> --></p><p id="p0004" num="0004">Analytical methods which have been used to detect or determine piperazine derivatives include GC-MS and LC-MS (Staack &amp; Maurer 2003; Antia <i>et al.,</i> 2010). Peters <i>et al.,</i> (2010) present a review of analytical toxicology of emerging drugs of abuse including piperazines. A disadvantage of mass spectrometry based methods of detection is that they require expensive equipment and highly trained staff. Immunoassays are known in the art as relatively cost effective, simplistic and rapid alternatives to mass-spectrometry based analysis. A commercially available MDMA immunoassay, the EMIT II plus Ecstasy Assay (SYVA/Dade Behring), has been shown to have cross-reactivity to BZP but concentrations of 3,000,000ng/mL were needed for a positive result (Logan <i>et al.,</i> 2010). Neogen have a specific benzylpiperazine ELISA kit available (Neogen Forensic Reference Brochure) however no data is provided for the detection of metabolites such as the important 4-OH metabolite nor is it indicated that the kit has the ability to detect these. Therefore there remains a need for a benzylpiperazine assay which is not only sensitive to the parent molecule but that can also detect key metabolites to enable improvements in the forensic toxicological and clinical analysis of the intake of this designer drug.</p><heading id="h0002"><b>References</b></heading><p id="p0005" num="0005"><ul><li><nplcit id="ncit0001" npl-type="s"><text>Antia, U. et al. (2009) Forensic Sci Int, 186(1-3):63-67</text></nplcit>.</li><li><nplcit id="ncit0002" npl-type="s"><text>Antia, U. et al. (2010) J Forensic Sci, 55(5):1311-1318</text></nplcit>.</li><li><nplcit id="ncit0003" npl-type="s"><text>Fitzgerald, S.P. et al. (2005). Clin. Chem., 51: 1165-1176</text></nplcit>.</li><li><nplcit id="ncit0004" npl-type="s"><text>Logan, B.K. et al. (2010) J Anal Toxicol, 34:587-589</text></nplcit>.</li><li><nplcit id="ncit0005" npl-type="s"><text>Peters, F.T. et al. (2010) Ther Drug Monit, 32(5): 532-539</text></nplcit>.</li><li><nplcit id="ncit0006" npl-type="s"><text>Staack, R.F. &amp; Maurer, H.H. (2003) J Anal Toxicol, 27(8):560-568</text></nplcit>.</li><li><nplcit id="ncit0007" npl-type="s"><text>Tsutsumi, H. et al. (2006) J Anal Toxicol, 30(1):38-43</text></nplcit>. http://www.neogen.com/Toxicology/pdf/Forensic_Reference_Brochure.pdf</li></ul></p><heading id="h0003"><b>Drawings</b></heading><p id="p0006" num="0006"><ul><li><figref idrefs="f0001">Figure 1</figref>: Chemical Structures of BZP and Related Compounds</li><li><figref idrefs="f0002">Figure 2</figref>: Chemical Reactions of the Synthesis of Hapten-1</li><li><figref idrefs="f0003">Figure 3</figref>: Chemical Reaction of the Synthesis of Hapten-2</li><li><figref idrefs="f0004">Figure 4</figref>: Chemical Reactions of the Synthesis of Hapten-3</li></ul><!-- EPO <DP n="3"> --></p><heading id="h0004"><b>Summary of the Invention</b></heading><p id="p0007" num="0007">The invention describes immunogens used in the production of novel polyclonal antibodies with unique binding properties which overcome the limitations of currently described immunoassays by enabling methods and kits for the detection and quantification of 1-Benzylpiperazine and its important metabolites 4-OH BZP and 3-OH BZP in <i>in vitro</i> patient samples. <figref idrefs="f0001">Figure 1</figref> shows the structures of these and other related molecules detected in the current invention.</p><p id="p0008" num="0008">According to a first aspect of the present invention, there is provided an immunogen having the general structure (I):
<chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="114" he="66" img-content="chem" img-format="tif"/></chemistry></p><p id="p0009" num="0009">Optionally, the accm (antigenicity conferring carrier material) is selected from bovine serum albumin (BSA), egg ovalbumin, bovine gamma globulin, bovine thyroglobulin (BTG), keyhole limpet haemocyanin (KLH), synthetic poly(amino acids) having a sufficient number of available amino groups, lysine, and synthetic or natural polymeric materials bearing reactive functional groups. Further optionally, the accm is bovine thyroglobulin (BTG).</p><p id="p0010" num="0010">Optionally, the cross-linker has the general structure (II):<!-- EPO <DP n="4"> -->
<chemistry id="chem0002" num="0002"><img id="ib0002" file="imgb0002.tif" wi="45" he="54" img-content="chem" img-format="tif"/></chemistry></p><p id="p0011" num="0011">Wherein, X, which is attached to the aromatic ring, is either a -C(O)-, O or NH; n=0 or 1, Y is a C<sub>1</sub>-C<sub>10</sub>, preferably a C<sub>1</sub>-C<sub>6</sub>, substituted or unsubstituted straight chain alkylene moiety, or arylene moiety, and Z (before conjugation with the accm) is selected from a carboxy, a dithiopyridyl, a maleimide, an amino, a hydroxyl, a thiol, a thioester or an aldehyde moiety.</p><p id="p0012" num="0012">According to a second aspect of the present invention, there is provided an antibody derivable from the immunogen of the first aspect of the present invention.</p><p id="p0013" num="0013">Optionally, the antibody is a polyclonal antibody. Alternatively, the antibody is a monoclonal antibody. Further alternatively, the antibody is a fragment, optionally a single chain variable fragment.</p><p id="p0014" num="0014">Optionally, the antibody according to the second aspect of the present invention has an IC<sub>50</sub> selected from one or more of about 1 ng/ml for 1-benzylpiperazine, about 1ng/ml for 4-OH benzylpiperazine, about 1ng/ml for 3-(Piperazin-1ylmethyl)phenol, about 1ng/ml for 1-Piperonylpiperazine and about 3 ng/ml for N-(3-Methylbenzyl)piperazine.</p><p id="p0015" num="0015">Further optionally, the antibody according to the second aspect of the present invention has an IC<sub>50</sub> selected from one or more of at least 1.4 ng/ml for 1-benzylpiperazine, 0.813 ng/ml for 4-OH benzylpiperazine, 1.137 ng/ml for 3-(Piperazin-1ylmethyl)phenol, 1.379 ng/ml for 1-Piperonylpiperazine and about 2.646 ng/ml for N-(3-Methylbenzyl)piperazine.</p><p id="p0016" num="0016">Optionally, the antibody according to the second aspect of the present invention is capable of binding to at least one epitope of an analyte selected from 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(Piperazin-1ylmethyl)phenol, 1-Piperonylpiperazine and N-(3-Methylbenzyl)piperazine.</p><p id="p0017" num="0017">Further optionally, the antibody has an IC<sub>50</sub> of about 1 ng/ml for 1-benzylpiperazine, about 1ng/ml for 4-OH benzylpiperazine, about 1ng/ml for 3-(Piperazin-1ylmethyl)phenol, about 1ng/ml for 1-Piperonylpiperazine and about 3 ng/ml for N-(3-Methylbenzyl)piperazine.<!-- EPO <DP n="5"> --></p><p id="p0018" num="0018">According to a third aspect of the present invention, there is provided a method of preparing an antibody capable of binding to at least one epitope of an analyte selected from 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(Piperazin-1ylmethyl)phenol, 1-Piperonylpiperazine and N-(3-Methylbenzyl)piperazine; the method comprising raising the antibody against the immunogen of the first aspect of the present invention.</p><p id="p0019" num="0019">Optionally, the raising step comprises preparing an antiserum. Further optionally, the raising step comprises preparing an antiserum by immunizing an animal. Still further optionally, the raising step comprises preparing an antiserum by immunizing an animal and isolating antibodies from the animal.</p><p id="p0020" num="0020">According to a fourth aspect of the present invention, there is provided an antibody derivable from the method according to the third aspect of the present invention.</p><p id="p0021" num="0021">Optionally, the antibody is a monoclonal antibody. Alternatively, the antibody is a polyclonal antibody. Further alternatively, the antibody is a fragment, optionally a single chain variable fragment.</p><p id="p0022" num="0022">Optionally, the antibody according to the fourth aspect of the present invention has an IC<sub>50</sub> selected from one or more of about 1 ng/ml for 1-benzylpiperazine, about 1ng/ml for 4-OH benzylpiperazine, about 1ng/ml for 3-(Piperazin-1ylmethyl)phenol, about 1ng/ml for 1-Piperonylpiperazine and about 3 ng/ml for N-(3-Methylbenzyl)piperazine.</p><p id="p0023" num="0023">Further optionally, the antibody according to the fourth aspect of the present invention has an IC<sub>50</sub> selected from one or more of at least 1.4 ng/ml for 1-benzylpiperazine, of at least 0.813 ng/ml for 4-OH benzylpiperazine, of at least 1.137 ng/ml for 3-(Piperazin-1ylmethyl)phenol, of at least 1.379 ng/ml for 1-Piperonylpiperazine and of at least 2.646 ng/ml for N-(3-Methylbenzyl)piperazine.</p><p id="p0024" num="0024">Optionally, the antibody according to the fourth aspect of the present invention is capable of binding to at least one epitope of an analyte selected from 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(Piperazin-1ylmethyl)phenol, 1-Piperonylpiperazine and N-(3-Methylbenzyl)piperazine. Further optionally, the antibody has an IC<sub>50</sub> of about 1 ng/ml for 1-benzylpiperazine, about 1ng/ml for 4-OH benzylpiperazine, about 1ng/ml for 3-(Piperazin-1ylmethyl)phenol, about 1ng/ml for 1-Piperonylpiperazine and about 3 ng/ml for N-(3-Methylbenzyl)piperazine.</p><p id="p0025" num="0025">According to a fifth aspect of the present invention, there is provided a method of detecting or determining one or more of 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(Piperazin-1ylmethyl)phenol, 1-Piperonylpiperazine and N-(3-Methylbenzyl)piperazine; the method comprising contacting a sample with the antibody according to the second aspect of the present invention or the antibody according to the fourth aspect of the present invention; detecting or determining the quantity of the antibody; and attributing the presence or amount of the antibody to the presence or amount of<!-- EPO <DP n="6"> --> one or more of 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(Piperazin-1ylmethyl)phenol, 1-Piperonylpiperazine and N-(3-Methylbenzyl)piperazine in the sample.</p><p id="p0026" num="0026">Optionally, the method comprises the further step of detecting or determining the quantity of a label or detecting agent capable of binding to the antibody according to the second aspect of the present invention or the antibody according to the fourth aspect of the present invention for detecting or determining the quantity of the antibody.</p><p id="p0027" num="0027">Also disclosed is an assay for detecting or determining one or more of 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(Piperazin-1ylmethyl)phenol, 1-Piperonylpiperazine and N-(3-Methylbenzyl)piperazine; the assay comprising the antibody according to the second aspect of the present invention or the antibody according to the fourth aspect of the present invention; and means for detecting or determining the quantity of the antibody to detect or determine the presence or amount of one or more of 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(Piperazin-1ylmethyl)phenol, 1-Piperonylpiperazine and N-(3-Methylbenzyl)piperazine in the sample.</p><p id="p0028" num="0028">Optionally, the assay further comprises a solid support to which the antibody is conjugated.</p><p id="p0029" num="0029">Also disclosed is a kit for detecting or determining one or more of 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(Piperazin-1ylmethyl)phenol, 1-Piperonylpiperazine and N-(3-Methylbenzyl)piperazine; the kit comprising the antibody according to the second aspect of the present invention or the antibody according to the fourth aspect of the present invention.</p><p id="p0030" num="0030">Optionally, the kit further comprises instruction for use.</p><heading id="h0005"><b>Detailed Description</b></heading><p id="p0031" num="0031">Unless otherwise stated technical terms as used herein are used according to the conventional usage as known to those skilled in the art.</p><p id="p0032" num="0032">The invention provides an immunogen of structure:<!-- EPO <DP n="7"> -->
<chemistry id="chem0003" num="0003"><img id="ib0003" file="imgb0003.tif" wi="92" he="44" img-content="chem" img-format="tif"/></chemistry>
in which the cross-linker is preferably:
<chemistry id="chem0004" num="0004"><img id="ib0004" file="imgb0004.tif" wi="41" he="56" img-content="chem" img-format="tif"/></chemistry>
wherein, X, which is attached to the aromatic ring, is either a -C(O)-, O or NH; n=0 or 1, Y is a C<sub>1</sub>-C<sub>10</sub>, preferably a C<sub>1</sub>-C<sub>6</sub>, substituted or unsubstituted straight chain alkylene moiety, or arylene moiety, and Z (before conjugation with the accm) is selected from a carboxy, a dithiopyridyl, a maleimide, an amino, a hydroxyl, a thiol, a thioester or an aldehyde moiety.</p><p id="p0033" num="0033">In the field of antibody development it is generally considered that the optimum length of the linking group joining the analyte to be detected to the accm (straight chain length and not including hydrogen atoms) is about 1- 10 atoms, more usually about 1-6 atoms.</p><p id="p0034" num="0034">Before conjugation to the accm the molecule can be referred to as a hapten. The term "hapten" as used herein describes a pre-immunogenic molecule that stimulates antibody production only when conjugated to a larger carrier molecule. Once the hapten is conjugated to the accm it forms the immunogen. The term "immunogen" as used herein, describes an entity that induces an immune response such as production of antibodies or a T-cell response in a host animal. The accm can be any material that makes all or part of the hapten susceptible to antibody recognition and binding. For example the accm can be a protein, a protein fragment, a synthetic polypeptide or a semi-synthetic<!-- EPO <DP n="8"> --> polypeptide. Illustrative examples of useful antigenicity-conferring carrier materials are bovine serum albumin (BSA), egg ovalbumin, bovine gamma globulin, bovine thyroglobulin (BTG), keyhole limpet haemocyanin (KLH) etc. Preferably the accm is BTG.</p><p id="p0035" num="0035">A further aspect of the invention is antibodies obtained from immunogens of the invention that bind to an epitope of 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(Piperazin-1ylmethyl)phenol, 1-Piperonylpiperazine and N-(3-Methylbenzyl)piperazine.</p><p id="p0036" num="0036">The term "antibody" as used herein refers to an immunoglobulin or immunoglobulin-like molecule. In a preferred embodiment of the current invention the antibodies are polyclonal antibodies but the skilled person will understand that any type of immunoglobulin molecule or fragment thereof can be used, for example monoclonal antibodies, Fab fragments, scFv fragments and any other antigen binding fragments all of which fall within the scope of the current invention. The polyclonal antibodies of the current invention may be produced by any method as known to those skilled in the art. Any suitable host animal may be used, preferably a mammalian animal for example, but not limited to sheep, rabbit, mouse, guinea pig or horse.</p><p id="p0037" num="0037">When used in reference to an antibody, the word 'specific' or 'specificity' in the context of the current invention refers to the analyte that is preferably bound by the antibody, as gauged by a suitable metric such as the cross-reactivity i.e. the analyte with the greatest cross-reactivity is the antibody specific analyte and is generally given a value of 100%, with all other analytes accorded a value relative to this; in addition, as is known by one skilled in the art, for cross-reactivity to be of practical use the analyte specific antibody must display a high sensitivity as measured by a suitable metric such as the IC<sub>50</sub>. The IC<sub>50</sub> is a common measure of antibody sensitivity for immunoassays. For the current invention, a high sensitivity is an IC<sub>50</sub> of less than 50ng/ml, preferably less than 10ng/ml, most preferably around 1ng/ml. In the current invention an IC<sub>50</sub> of around 1ng/ml refers to antibodies with IC<sub>50</sub> values from about 0.5ng/ml and above. It is recognized that for immunoassays that utilize a competitive format, the exact IC<sub>50</sub> value varies slightly depending on the nature of the detecting agent used to compete with the analyte in the sample. The high sensitivity of the current antibodies to BZP and 4-OH BZP, as measured by IC<sub>50</sub>, enables the use of the antibodies in toxicological applications.</p><p id="p0038" num="0038">A further aspect of the invention is antibodies that have an IC<sub>50</sub> of about 1 ng/ml for 1-benzylpiperazine, about 1ng/ml for 4-OH benzylpiperazine, about 1ng/ml for 3-(Piperazin-1ylmethyl)phenol, about 1ng/ml for 1-Piperonylpiperazine and about 3 ng/ml for N-(3-Methylbenzyl)piperazine.</p><p id="p0039" num="0039">A still further aspect of the invention is antibodies that have an IC<sub>50</sub> of at least 1.4 ng/ml for 1-benzylpiperazine, of at least 0.813 ng/ml for 4-OH benzylpiperazine, of at least 1.137 ng/ml for 3-(Piperazin-1ylmethyl)phenol,<!-- EPO <DP n="9"> --> of at least 1.379 ng/ml for 1-Piperonylpiperazine and of at least 2.646 ng/ml for N-(3-Methylbenzyl)piperazine. It is known to the skilled person that by varying the antibody concentration through dilution, that the IC<sub>50</sub> values can be adjusted depending upon the application.</p><p id="p0040" num="0040">The invention also provides methods of detecting or determining one or more of 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(Piperazin-1ylmethyl)phenol, 1-Piperonylpiperazine and N-(3-Methylbenzyl)piperazine in an <i>in vitro</i> sample of an individual or an environmental sample comprising; contacting the sample with one or more detecting agents and one or more antibodies of the invention; detecting, or determining the quantity of, the one or more detecting agents; and deducing from calibrators, the presence of or amount of one or more of 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(Piperazin-1ylmethyl)phenol, 1-Piperonylpiperazine and N-(3-Methylbenzyl)piperazine in the sample. 'Detecting' as referred to herein means qualitatively analyzing for the presence or absence of a substance, while 'determining' means quantitatively analyzing for the amount of a substance. The detecting agent is a small molecule (generally of similar structure to a molecule to be detected), conjugated to a labelling/detecting agent that is able to bind to one of the antibodies of the invention. The labelling agent is selected from an enzyme, a luminescent substance, a radioactive substance, or a mixture thereof. Preferably, the labelling agent is an enzyme, preferably a peroxidase, most preferably horseradish peroxidase (HRP). Alternatively, or additionally, the luminescent substance may be a bioluminescent, chemiluminescent or fluorescent material. For the purposes of the invention, the patient sample to be used for <i>in vitro</i> analysis can be hair or a peripheral biological fluid but is preferably whole blood, serum, plasma, or urine.</p><p id="p0041" num="0041">A further aspect of the invention is a kit for detecting or determining one or more of 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(Piperazin-1ylmethyl)phenol, 1-Piperonylpiperazine and N-(3-Methylbenzyl)piperazine comprising one or more antibodies of the invention. Optionally, the kit may contain one or more detecting agents and one or more calibrators.</p><heading id="h0006"><b>General Methods, Examples and Results</b></heading><heading id="h0007"><u>Preparation of Haptens, Immunogens and Detecting Agents</u></heading><p id="p0042" num="0042">Although haptens provide defined structural epitopes, they are not in themselves immunogenic and therefore need to be conjugated to carrier materials, which will elicit an immunogenic response when administered to a host animal. Appropriate carrier materials commonly contain poly(amino acid) segments and include polypeptides, proteins and protein<!-- EPO <DP n="10"> --> fragments. Illustrative examples of useful carrier materials are bovine serum albumin (BSA), egg ovalbumin, bovine gamma globulin, bovine thyroglobulin (BTG), keyhole limpet haemocyanin (KLH) etc. Alternatively, synthetic poly(amino acids) having a sufficient number of available amino groups, such as lysine, may be employed, as may other synthetic or natural polymeric materials bearing reactive functional groups The coupling chemistry used to prepare an immunogen from a hapten and carrier protein is an important consideration for the successful production and the correct specificity of the resultant antibodies. The choice of cross-linking methodology is governed both by the functional groups present on the carrier protein and the hapten, and by the orientation of the hapten desired for appropriate presentation to the immune system. Also, carbohydrates, yeasts or polysaccharides may be conjugated to the hapten to produce an immunogen. The haptens can also be coupled to a detectable labelling agent such as an enzyme (for example, horseradish peroxidase), a substance having fluorescent properties or a radioactive label for the preparation of detecting agents (conjugates) for use in the immunoassays. The carbodiimide first reacts with available carboxylic groups of the haptens to form a highly active O-acylisourea intermediate. The activated carboxylic group the react with the primary amine to form an amide bond, with the release of the EDC mediator as a soluble isourea derivative. The fluorescent substance may be, for example, a monovalent residue of fluorescein or a derivative thereof. Immunogen formation for the invention described herein involves conventional conjugation chemistry as described in "<nplcit id="ncit0008" npl-type="b"><text>Bioconjugation Techniques" by Greg T. Hermanson, Academic Press, pages 419- 455</text></nplcit> and "<nplcit id="ncit0009" npl-type="s"><text>Bioconjugation" by Mohammed Aslam and Alastair Dent, ISBN 1-56159-161-0 (1998) pages 364-482</text></nplcit>. In order to confirm that adequate conjugation of the hapten to carrier material has been achieved, prior to immunisation, each immunogen is evaluated using matrix-assisted UV laser desorption /ionisation time-of-flight mass spectroscopy (MALDI-TOF MS).</p><heading id="h0008"><u>General Procedure for MALDI-TOF Analysis of Immunogens.</u></heading><p id="p0043" num="0043">MALDI-TOF mass spectrometry was performed using a Voyager STR Biospectrometry Research Station laser-desorption mass spectrometer coupled with delayed extraction in accordance with the manufacturer's instruction. An aliquot of each sample to be analysed was diluted in 0.1% aqueous trifluoroacetic acid (TFA) to create 1mg/ml sample solutions.<!-- EPO <DP n="11"> --> Aliquots (1µl) were analysed using a matrix of sinapinic acid and bovine serum albumin (Fluka) was used as an external calibrant.</p><heading id="h0009"><u>Preparation of Antisera</u></heading><p id="p0044" num="0044">In order to generate polyclonal antisera, 2mg of an immunogen of the present invention is prepared in PBS, mixed at a ratio of 50% Immunogen in PBS with 50% Freund's Complete adjuvant (Sigma, Product Number -F5881) and emulsified by repeatedly passing the mixture through a tip on the end of a 1ml syringe, until it reaches the required semi-solid consistency. 1ml of the mixture is then injected into a host animal, such as rabbit, sheep, mouse, guinea pig or horse. Sheep are the preferred host animal. Further injections (boosts) are administered on a monthly basis (1mg of immunogen is prepared in PBS and mixed at a ratio of 50% Immunogen in PBS with 50% of Freunds Incomplete Adjuvent, Sigma product Number - F5506) until the required titre is achieved. Serum is sampled for evaluation of the antibody titre.</p><p id="p0045" num="0045">Briefly, blood is collected by applying pressure to the exposed jugular vein and inserting a clean 14 gauge hypodermic needle to remove 500ml of blood per sheep, under gravity. The blood is stored at 37°C for a minimum of 1 hour before the clots are separated from the side of the centrifuge bottles using disposable 1ml pipettes (ringing). The samples are stored at 4°C overnight.</p><p id="p0046" num="0046">Samples are then centrifuged at 4200rpm for 30 minutes at 4°C. The serum is poured off and centrifuged again, at 10,000rpm for 15 minutes at 4°C, before being aliquoted and stored at &lt;-20°C.</p><p id="p0047" num="0047">The Immunoglobulin (Ig) fraction is extracted from the antisera via caprylic acid/ammonium sulphate precipitation of immunoglobulin.</p><p id="p0048" num="0048">The antibody titre is evaluated by coating a microtitre plate (Thermo Fisher Scientific NUNC, 468667) with antibody (125µl/well) in coating buffer (10mM Tris pH 8.5) at 37°C for 2 hours. The plate is then washed 4 times over 10 minutes with working strength TBST. 50µl of sample/standard (1-Benzylpiperazine) is added to the appropriate wells in triplicate, followed by 75µl of hapten-HRP conjugate and incubated at 25°C for 1 hour. The plate is then washed and 125µl of TMB (Randox, 4380-15) added to each well and left at room temperature for 20mins in the dark. The reaction is stopped using 125µl of 0.2M sulphuric<!-- EPO <DP n="12"> --> acid. The absorbances are read at 450nm with an ELISA microplate reader (BIO-TEK Instruments, Elx800) and the means calculated. Antibody sensitivity can then be determined.</p><p id="p0049" num="0049">When the optimal titre has been attained, the host animal is bled to yield a suitable volume of specific antiserum (overall this results in 20 bleeds in total, with approximately 200ml of antiserum achieved per bleed). The degree of antibody purification required depends on the intended application. For many purposes, there is no requirement for purification, however, in other cases, such as where the antibody is to be immobilised on a solid support, purification steps can be taken to remove undesired material and eliminate non-specific binding.</p><p id="p0050" num="0050">Various purification steps are available if required, including Immunoglobulin Precipitation (as described above), Antigen-specific affinity purification, Size-exclusion chromatography and Ion Exchange Chromatography.</p><heading id="h0010"><u>Immunoassay Development</u></heading><p id="p0051" num="0051">The process of developing an immunoassay is well known to the person skilled in the art. Briefly, for a competitive immunoassay in which the target analyte is a non-immunogenic molecule such as a hapten, the following process is conducted: antibodies are produced by immunizing an animal, preferably a mammalian animal, by repeated administration of an immunogen. The serum from the immunized animal is collected when the antibody titre is sufficiently high. A detecting agent is added to a sample containing the target analyte and the raised antibodies, and the detecting agent and analyte compete for binding to the antibodies. The process may comprise fixing said serum antibodies to a backing substrate such as a polystyrene solid support or a ceramic chip. The antibodies can be polyclonal or monoclonal antibodies.</p><p id="p0052" num="0052">This can be carried out using an ELISA based format as described above for measuring antibody titre or as a Biochip based format. Details of how the antibodies are fixed to the Biochip are described in <nplcit id="ncit0010" npl-type="s"><text>FitzGerald, S. P. et al, Clin. Chem. 51(7); 1165-1176; 2005</text></nplcit>. The signal emitted in the immunoassay is proportionate to the amount of detecting agent bound to the antibodies which in turn is inversely proportionate to the analyte concentration. The signal can be detected or quantified by comparison with a calibrator.<!-- EPO <DP n="13"> --></p><heading id="h0011"><b>EXAMPLES</b></heading><heading id="h0012">(Numbers in bold refer to structures in figure 2 or figure 4)</heading><heading id="h0013"><b>Example -1: Preparation 4-hydroxybenzylpiperazine</b> 2</heading><p id="p0053" num="0053">To a solution of hydrobromic acid 48% in water (100ml) was added 4-methoxybenzylpiperazine hydrochloride <b>1</b> (10g, 41.2 mM) and the suspension was heated at reflux for 4 hours. The solution was then cooled to room temperature and concentrated to dryness to give a solid. Water was then added to the solid and the solution was stirred for 1 hour. The solid was then filtered, washed by water and dried at high vacuum to give the 4-hydroxybenzylpiperazine dihydrobromide <b>2</b> (6.3g, 43.2%)</p><heading id="h0014"><b>Example - 2: Preparation of N-boc-4-hydroxybenzylpiperazine 3</b></heading><p id="p0054" num="0054">To a suspension of 4-hydroxybenzylpiperazine dihydrobromide <b>2</b> (6g, 18.9mM) in dichloromethane (150ml) was added TEA (3.15ml, 22.7mM) and BOC anhydride (4.9g, 22.6mM) and the mixture was stirred at room temperature overnight. The solution was then washed by water (1x100ml), brine (1x100ml), dried over sodium sulphate, filtered and concentrated to dryness. The crude product obtained was purified by flash chromatography on silica gel using ethyl acetate / hexane (50 / 50) to give the N-boc-4-hydroxybenzylpiperazine <b>3</b> (4.1g, 74.2%).</p><heading id="h0015"><b>Example - 3: Preparation of the ester 4</b></heading><p id="p0055" num="0055">To a suspension of sodium hydride (NaH) (0.551g, 16.4mm) in dimethylformamide (DMF) (50ml) under nitrogen was added drop-wise a solution of N-boc-4-hydoxybenzylpiperazine <b>3</b> (4.0g, 13.7mM) in DMF (25ml) and the mixture was stirred and heated at 60°C for 1 hour. The mixture was then cooled to room temperature and to it was added drop-wise a solution of ter-butyl bromoacetate (3.2g, 16.4mM) in DMF (25ml) and the mixture was stirred and heated at 60°C for 4 hours. The solution was then cooled to RT and the DMF was removed under vacuum. Ethyl acetate (200ml) was added to the crude product and then washed by water (100ml) and brine. The solution was then dried over sodium sulphate, filtered and concentrated to dryness. The crude product obtained was purified by chromatography on silica gel using ethyl acetate / hexane (1 / 1) to give the ester <b>4</b> (4.0g, 72%) as a clear oil.<!-- EPO <DP n="14"> --></p><heading id="h0016"><b>Example - 4: Preparation of the 2-[4-(piperazin-1-yl-methyl)phenoxy] acetic acid TFA salt (Hapten-1)</b></heading><p id="p0056" num="0056">To a solution of the ester <b>4</b> (3.5g, 8.6mM) in dichloromethane (60ml) was added trifluoroacetic acid (TFA) (30ml) and the solution was stirred at RT overnight. The solution was concentrated to dryness and the crude product obtained was triturated with ether to give a white solid of the <b>hapten-1</b> as TFA salt (2.7g, 86%) as TFA salt. (As illustrated in <figref idrefs="f0002">Figure 2</figref>)</p><heading id="h0017"><b>Example 5: Conjugation of Hapten-1 to BSA (Immunogen-I)</b></heading><p id="p0057" num="0057">To a solution of 2-[4-(piperazin-1-yl-methyl)phenoxy] acetic acid TFA salt (<b>Hapten-1</b>) (49.5mg, 0.15mM) in DMF (1.0ml) was added N, N-dicyclohexylcarbodiimide (DCC) (33.08mg, 0.16mM) and N-hydroxysuccinimide (18.7mg, 0.16mM) and the mixture was stirred at room temperature overnight. The dicyclohexylurea formed was removed by filtration and the solution was added drop-wise to a solution of BSA (150mg, 2.3µmol) in 50mM sodium bicarbonate solution (pH 8.5) (10ml). The mixture was then stirred overnight at 4° C. The solution was then dialysed against 50mM phosphate buffer pH 7.2 (3 changes) for 24 hours at 4° C, and freeze-dried.</p><p id="p0058" num="0058">MALDI results showed 11.95 molecules of hapten -1 had been conjugated to one molecule of BSA.</p><heading id="h0018"><b>Example 6: Conjugation of Hapten-1 to BTG (Immunogen-II)</b></heading><p id="p0059" num="0059">To a solution of 2-[4-(piperazin-1-yl-methyl)phenoxy] acetic acid TFA salt (<b>Hapten-1</b>) (61.99mg, 0.203mmol) in DMF (1.0ml) was added N, N-dicyclohexylcarbodiimide (DCC) (46.01mg, 0.223mmol) and N-hydroxysuccinimide (25.66mg, 0.223mmol) and the mixture was stirred at room temperature overnight. The dicyclohexylurea formed was removed by filtration and the solution was added drop wise to a solution of BTG (150mg, 2.25µmol) in 50mM sodium bicarbonate solution (pH 8.5) (10ml). The mixture was then stirred overnight at 4° C. The solution was then dialysed against 50mM phosphate buffer pH 7.2 (3 changes) for 24 hours at 4° C, and freeze-dried</p><heading id="h0019"><b>Example 7: Conjugation of Hapten-1 to HRP</b></heading><p id="p0060" num="0060">EDC hydrochloride (10mg) was dissolved in water (0.5ml) and immediately added to a solution of 2-[4-(piperazin-1-yl-methyl)phenoxy] acetic acid TFA salt (<b>Hapten-1</b>) (2mg) in DMF (0.2ml). After<!-- EPO <DP n="15"> --> mixing, this solution was added drop wise to a solution of HRP (20mg) in water (1ml). Sulfo-NHS (5mg) was added and the reaction mixture was incubated in the dark at room temperature overnight. Excess hapten was removed with double PD-10 columns (Pharmacia) in series, pre-equilibrated with PBS at pH 7.2. The hapten-HRP conjugate was then dialysed overnight against 10L of PBS at pH 7.2 at 4° C.</p><heading id="h0020"><b>Example 8: Preparation of ter-butyl 4-(4-benzylpiperazin-1-yl) propionate</b></heading><p id="p0061" num="0061">To a solution of 1-benzylpiperazine (8.813g, 0.05mol) in acetonitrile (200ml) under nitrogen was added triethylamine (TEA) (16.7ml, 0.12mol) and ter-butyl acrylate (15.4g, 0.12mol) and the mixture was stirred at reflux overnight. The solution was then cooled to RT and concentrated to dryness. Ethyl acetate (300ml) was then added and the ethyl acetate phase was washed by water (200ml), brine (200ml), dried over sodium sulfate, filtered and concentrated to dryness. The crude product obtained was purified by chromatography on silica gel using 70% ethyl acetate, 30% hexane to give the ter-butyl 4-(4-benzylpiperazin-1-yl) propionate <b>5</b> as an oil (12.6g, 83%).</p><heading id="h0021"><b>Example 9: Preparation of 4-(4-benzylpiperazin-1-yl) propionic acid TFA salt (Hapten - 3)</b></heading><p id="p0062" num="0062">To a solution ter-butyl 4-(4-benzylpiperazin-1-yl) propionate <b>5</b> (12.2g, 0.04mol) in dichloromethane (200ml) was added trifluoroacetic acid (TFA) (50ml) and the mixture was then stirred at RT for 6 hours. The mixture was concentrated to dryness and the crude product obtained was triturated with ether and the solid formed was filtered, washed with ether and dried under vacuum overnight to give 4-(4-benzylpiperazin-1-yl) propionic acid TFA salt (<b>Hapten - 3</b>) (10.5, 72%). (As illustrated in <figref idrefs="f0004">figure 4</figref>)</p><heading id="h0022"><b>Example 10: Conjugation of Hapten-3 to BSA (Immunogen-III)</b></heading><p id="p0063" num="0063">To a solution of 4-(4-benzylpiperazin-1-yl) propionic acid TFA salt (<b>Hapten - 3</b>) (54.35mg, 0.15mM) in DMF (1.0ml) was added N, N-dicyclohexylcarbodiimide (DCC) (33.08mg, 0.16mM) and N-hydroxysuccinimide (18.7mg, 0.16mM) and the mixture was stirred at room temperature overnight. The dicyclohexylurea formed was removed by filtration and the solution was added drop-wise to a solution of BSA (150mg, 2.3µmol) in 50mM sodium bicarbonate solution (pH 8.5) (10ml). The mixture was then stirred overnight at 4° C. The solution was then dialysed against 50mM phosphate buffer pH 7.2 (3 changes) for 24 hours at 4° C, and freeze-dried.</p><p id="p0064" num="0064">MALDI results showed 6.03 molecules of hapten -3 had been conjugated to one molecule of BSA.<!-- EPO <DP n="16"> --></p><heading id="h0023"><b>Example 11: Conjugation of Hapten-3 to BTG (Immunogen-IV)</b></heading><p id="p0065" num="0065">To a solution of 4-(4-benzylpiperazin-1-yl) propionic acid TFA salt (<b>Hapten - 3</b>) (73.55mg, 0.203mmol) in DMF (1.0ml) was added N, N-dicyclohexylcarbodiimide (DCC) (46.01mg, 0.223mmol) and N-hydroxysuccinimide (25.66mg, 0.223mmol) and the mixture was stirred at room temperature overnight. The dicyclohexylurea formed was removed by filtration and the solution was added drop wise to a solution of BTG (150mg, 2.25µmol) in 50mM sodium bicarbonate solution (pH 8.5) (10ml). The mixture was then stirred overnight at 4° C. The solution was then dialysed against 50mM phosphate buffer pH 7.2 (3 changes) for 24 hours at 4° C, and freeze-dried.</p><heading id="h0024"><b>Example 12: Conjugation of Hapten-3 to HRP</b></heading><p id="p0066" num="0066">EDC hydrochloride (10mg) was dissolved in water (0.5ml) and immediately added to a solution of 4-(4-benzylpiperazin-1-yl) propionic acid TFA salt (<b>Hapten - 3</b>) (2mg) in DMF (0.2ml). After mixing, this solution was added drop wise to a solution of HRP (20mg) in water (1ml). Sulfo-NHS (5mg) was added and the reaction mixture was incubated in the dark at room temperature overnight. Excess hapten was removed with double PD-10 columns (Pharmacia) in series, pre-equilibrated with PBS at pH 7.2. The hapten-HRP conjugate was then dialysed overnight against 10L of PBS at pH 7.2 at 4° C.</p><heading id="h0025"><b>Example 13: Development of a biochip Immunoassay</b></heading><p id="p0067" num="0067">Pre-immunisation blood samples were collected from 16-month-old female Suffolk sheep. The immunisation mixture was prepared by adding 2mg of immunogen prepared in PBS at a ratio of 50% Immunogen/PBS with 50% Freund's Complete adjuvant (Sigma, Product Number -F5881) and emulsifying the mixture to prepare the final product for immunisation. On Day 0, each sheep was immunized intramuscularly with 1ml of the mixture described above, with 2-[4-(piperazin-1-yl-methyl)phenoxy] acetic acid conjugated to a carrier protein bovine thyroglobulin (BTG) (as in example 6 above). Subsequent boosts (a total of 20 boosts) were administered intramuscularly to each sheep every 30 days. Freund's complete adjuvant (Sigma, Product Number -F5881) was used for primary immunizations and Freund's incomplete adjuvant (Sigma product Number -F5506) was used for all subsequent injections. Routine bleeds were taken between boosts to monitor the antibody titre and sensitivity, using hapten 1 conjugated to Horseradish peroxidase in a competitive ELISA, testing cross reactivity to 1-Benzylpiperazine and 4-OH benzylpiperazine.<!-- EPO <DP n="17"> --></p><p id="p0068" num="0068">Once the antibody titres were assessed as meeting the required performance criteria i.e. there was no significant increase in antibody titre and a plateau had been reached in the % displacement profile, antibodies were then evaluated by competitive immunoassay. They were first immobilized on a biochip platform (9mm x 9mm) (Randox Laboratories Ltd.), which was the vessel for the immunoreactions. The semi-automated bench top analyser Evidence Investigator was used (EV3602, Randox Laboratories Ltd., Crumlin, UK, patents-<patcit id="pcit0001" dnum="EP98307706A"><text>EP98307706</text></patcit>, <patcit id="pcit0002" dnum="EP98307732A"><text>EP98307732</text></patcit>, <patcit id="pcit0003" dnum="EP0902394A"><text>EP0902394</text></patcit>, <patcit id="pcit0004" dnum="EP1227311A"><text>EP1227311</text></patcit>, <patcit id="pcit0005" dnum="EP1434995A"><text>EP1434995</text></patcit> and <patcit id="pcit0006" dnum="EP1354623A"><text>EP1354623</text></patcit>). The assay principle was based on competition for binding sites of the polyclonal antibodies between free antigen (1-Benzylpiperazine and other cross-reactants) and labelled conjugate (Hapten 1-HRP, prepared as in example 6). Assay dilutent (155µl), calibrator/1-benzylpiperazine or potential cross-reactant (25µl) followed by Hapten 1-HRP conjugate (120µl) were added to the appropriate biochip. The biochips were then incubated for 30 minutes at 30°C on a thermo-shaker set at 370 rpm. The biochips were then subjected to 2 quick wash cycles using the wash buffer provided, followed by 4 x 2 minute wash cycles. 250µl of signal (1:1 luminol + peroxide, v/v) was then added to each biochip, and after 2 minutes the biochip carrier was imaged in the Evidence Investigator analyser. The system incorporates dedicated software to automatically process, report and archive the data generated (details can be found in <nplcit id="ncit0011" npl-type="s"><text>FitzGerald, S. P. et al, Clin. Chem. 51(7); 1165-1176; 2005</text></nplcit>).<!-- EPO <DP n="18"> --></p><heading id="h0026"><b>Results</b></heading><p id="p0069" num="0069">Calibration curves were generated using the Biochip based immunoassay as described above. The IC<sub>50</sub> was calculated from the graphs by taking 50% of the signal from the zero calibrator and reading the corresponding value on the <i>x</i>-axis, equivalent to the concentration of unlabelled ligand which reduces specific binding of labelled ligand by 50%. Specificity was also tested against a range of related analytes (Table 1). Cross-reactivity was calculated according to the following formula: <maths id="math0001" num=""><math display="block"><mo>%</mo><mi>CR</mi><mo>=</mo><msub><mi>IC</mi><mn mathvariant="normal">50</mn></msub><mo>,</mo><mn mathvariant="normal">1</mn><mo>-</mo><mi>benzylpiperazine</mi><mo>/</mo><msub><mi>IC</mi><mrow><mn mathvariant="normal">50</mn><mo>,</mo><mi>CR</mi></mrow></msub><mspace width="1em"/><mi mathvariant="normal">X</mi><mspace width="1em"/><mn mathvariant="normal">100</mn></math><img id="ib0005" file="imgb0005.tif" wi="87" he="13" img-content="math" img-format="tif"/></maths></p><p id="p0070" num="0070">Where %CR is the percentage cross-reactivity, IC<sub>50</sub>, 1-benzylpiperazine is the concentration of 1-benzylpiperazine that causes 50% displacement of signal and IC<sub>50</sub>, <sub>CR</sub> is the concentration of 1-benzylpiperazine/metabolites/structurally-related molecules that causes 50% displacement of signal.
<tables id="tabl0001" num="0001"><img id="ib0006" file="imgb0006.tif" wi="149" he="78" img-content="table" img-format="tif"/></tables></p></description><claims mxw-id="PCLM56977480" lang="EN" load-source="patent-office"><!-- EPO <DP n="19"> --><claim id="c-en-0001" num="0001"><claim-text>An immunogen having the general structure (I):
<chemistry id="chem0005" num="0005"><img id="ib0007" file="imgb0007.tif" wi="103" he="62" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="c-en-0002" num="0002"><claim-text>The immunogen of claim 1, wherein the cross-linker has the general structure (II):
<chemistry id="chem0006" num="0006"><img id="ib0008" file="imgb0008.tif" wi="57" he="55" img-content="chem" img-format="tif"/></chemistry>
Wherein, X, which is attached to the aromatic ring, is either a -C(O)-, O or NH; n=0 or 1, Y is a C<sub>1</sub>-C<sub>10</sub>, preferably a C<sub>1</sub>-C<sub>6</sub>, substituted or unsubstituted straight chain alkylene moiety, or arylene moiety, and Z (before conjugation with the accm) is selected from a carboxy, a dithiopyridyl, a maleimide, an amino, a hydroxyl, a thiol, a thioester or an aldehyde moiety</claim-text></claim><claim id="c-en-0003" num="0003"><claim-text>An antibody derivable from an immunogen of any of Claims 1 or 2.</claim-text></claim><claim id="c-en-0004" num="0004"><claim-text>The antibody of Claim 3 capable of binding to at least one epitope of an analyte selected from 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(piperazin-1ylmethyl)phenol, 1-piperonylpiperazine and N-(3-methylbenzyl)piperazine.<!-- EPO <DP n="20"> --></claim-text></claim><claim id="c-en-0005" num="0005"><claim-text>The antibody of Claim 4 having an IC<sub>50</sub> selected from one or more of about 1 ng/ml for 1-benzylpiperazine, about 1ng/ml for 4-OH benzylpiperazine, about 1ng/ml for 3-(piperazin-1ylmethyl)phenol, about 1ng/ml for 1-piperonylpiperazine and about 3 ng/ml for N-(3-methylbenzyl)piperazine.</claim-text></claim><claim id="c-en-0006" num="0006"><claim-text>A method of preparing an antibody capable of binding to at least one epitope of an analyte selected from 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(piperazin-1ylmethyl)phenol, 1-piperonylpiperazine and N-(3-methylbenzyl)piperazine; the method comprising raising the antibody against the immunogen of any of Claims 1 or 2.</claim-text></claim><claim id="c-en-0007" num="0007"><claim-text>An antibody derivable from the method of Claim 6.</claim-text></claim><claim id="c-en-0008" num="0008"><claim-text>The antibody of Claim 7 having an IC<sub>50</sub> selected from one or more of about 1 ng/ml for 1-benzylpiperazine, about 1ng/ml for 4-OH benzylpiperazine, about 1ng/ml for 3-(piperazin-1ylmethyl)phenol, about 1ng/ml for 1-piperonylpiperazine and about 3 ng/ml for N-(3-methylbenzyl)piperazine.</claim-text></claim><claim id="c-en-0009" num="0009"><claim-text>A method of detecting or determining one or more of 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(piperazin-1ylmethyl)phenol, 1-piperonylpiperazine and N-(3-methylbenzyl)piperazine; the method comprising contacting a sample with an antibody of any of Claims 3 to 5 or Claims 7-8, and one or more detecting agents; detecting, or determining the quantity of, the one or more detecting agents; and deducing from calibrators, the presence of or amount of one or more of 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(piperazin-1ylmethyl)phenol, 1-piperonylpiperazine and N-(3-methylbenzyl)piperazine in the sample.</claim-text></claim><claim id="c-en-0010" num="0010"><claim-text>An assay for detecting or determining one or more of 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(Piperazin-1ylmethyl)phenol, 1-Piperonylpiperazine and N-(3-Methylbenzyl)piperazine; the assay comprising the antibody of any of the Claims 3-5 or Claims 7-8; and means for detecting or determining the quantity of the antibody to detect or determine the presence or amount of one or more of 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(piperazin-1ylmethyl)phenol, 1-piperonylpiperazine and N-(3-methylbenzyl)piperazine in the sample.</claim-text></claim><claim id="c-en-0011" num="0011"><claim-text>A kit for detecting or determining one or more of 1-benzylpiperazine, 4-OH benzylpiperazine, 3-(piperazin-1ylmethyl)phenol, 1-piperonylpiperazine and N-(3-methylbenzyl)piperazine; the kit comprising the antibody of any of Claims 3 to 5 or Claims 7-8.</claim-text></claim></claims><drawings mxw-id="PDW16668173" load-source="patent-office"><!-- EPO <DP n="21"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="150" he="125" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="22"> --><figure id="f0002" num="2"><img id="if0002" file="imgf0002.tif" wi="151" he="185" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="23"> --><figure id="f0003" num="3"><img id="if0003" file="imgf0003.tif" wi="156" he="166" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="24"> --><figure id="f0004" num="4"><img id="if0004" file="imgf0004.tif" wi="148" he="130" img-content="drawing" img-format="tif"/></figure></drawings><search-report-data><doc-page id="srep0001" file="srep0001.tif" wi="160" he="233" type="tif"/><doc-page id="srep0002" file="srep0002.tif" wi="160" he="233" type="tif"/><doc-page id="srep0003" file="srep0003.tif" wi="153" he="233" type="tif"/></search-report-data><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
